Idenix Hepatitis C Agent To Enter Phase III In Early 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Idenix expects to finalize its valopicitabine Phase III trial protocol by March 2006 for treatment-refractory hepatitis C patients and begin enrollment shortly thereafter